STIMIT Enrolls Patients in Trial for Noninvasive Diaphragm Neurostimulation Device
STIMIT AG announced today that it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, the “STIMIT ACTIVATOR 1 PIVOTAL STUDY,” in collaboration with leading clinical centers worldwide. The trial will assess the safety and effectiveness of…
Signature Healthcare Partners with NRC Health to Enhance Patient Experience and Workforce Engagement
Signature Healthcare has partnered with NRC Health to strengthen its network with human-centered healthcare solutions and advanced, data-driven insights that foster a deeper understanding of patients, employees, and communities. This collaboration supports Signature Healthcare’s mission to become the leading community-based…
Laekna Partners with Lilly to Develop LAE102, Monoclonal Antibody for Obesity
Laekna, Inc. (2105.HK), a global biotech company focused on developing novel therapies for metabolic and cancer diseases, is excited to announce a clinical collaboration with Eli Lilly and Company (Lilly), a leader in cardiometabolic health, including diabetes and obesity. The…
DT Research and swyMed Power Washington County Medical Center’s EMS Telemedicine Services
DT Research, a leading provider of purpose-built computing solutions for vertical markets, and swyMed™, a top provider of telemedicine and connectivity solutions, announced that Washington County Regional Medical Center (WCRMC) is using their technologies for its EMS telemedicine services, supported…
MediaLab Rebrands as Vastian, Expands into Hospital Quality and Accreditation
After nearly 30 years as a leader in lab quality management, MediaLab has announced its rebrand to Vastian. This change reflects the company’s growth and expansion to address the broader quality and accreditation needs of hospitals and health systems. Vastian…
Puma Biotechnology Launches ALISCA™-Breast1 Phase II Trial of Alisertib in HR+/HER2- Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has announced the launch of its ALISCA™-Breast1 Phase II trial (PUMA-ALI-1201; NCT06369285). The study will evaluate alisertib, in combination with endocrine therapy, for the treatment of hormone receptor-positive (HR+), HER2-negative recurrent or…
Tanner Becomes First Community Cancer Care Provider to Offer Varian’s HyperSight
Tanner Cancer Care’s newly expanded Roy Richards, Sr. Cancer Center is not only visually impressive but also features the latest advancements in cancer treatment technology. Tanner Cancer Care’s newly expanded Roy Richards, Sr. Cancer Center is now the first community…
Pharmanovia In-Licenses Catumaxomab from Lindis Biotech for Malignant Ascites
Pharmanovia, a global pharmaceutical company focused on commercializing innovative medicines and revitalizing established ones, today announced the expansion of its oncology portfolio with a new licensing agreement for catumaxomab. This agreement will enable the treatment of malignant ascites, a rare…
Study in Heart Rhythm Shows AI Algorithms Cut Alert Burden with PaceMate’s Data Capabilities
A recent study published in Heart Rhythm highlights how artificial intelligence (AI) algorithms embedded in Medtronic’s LINQ II implantable loop recorders (ILRs) significantly reduce alert and episode burdens. This is achieved through data analysis powered by PaceMate’s flagship product, PaceMateLIVE™.…
Peek Launches First-Ever ‘Prescription Marketplace’ to Revolutionize Employer Benefits
While every company wants to support their employees’ health, businesses of all sizes face challenges with rising healthcare costs and complex, confusing benefit plans. Prescription medications can be a tough challenge for many people. Faced with the decision of whether…
Sangamo Therapeutics Gets FDA IND Clearance for ST-503 in Treating Idiopathic Small Fiber Neuropathy
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for its ST-503 program. ST-503 is an experimental epigenetic regulator being developed…
Rocket Pharmaceuticals Publishes Phase 1 RP-A501 Data in NEJM, Presents at AHA Conference 2024
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading biotechnology company focused on developing genetic therapies for rare, life-threatening diseases, announced promising long-term safety and efficacy data from its Phase 1 RP-A501 study. The results were presented at the 2024 American Heart…